Association of primary-site surgery with survival in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma: a population-based SEER study (2004–2023)

Description

Longlian Deng and co-authors asked whether removing the main tumor helps patients whose gut or pancreas neuroendocrine cancer has already spread. Their 2026 study used a United States cancer registry covering 2004 to 2023 and found 4,033 patients with distant spread. Of these, 786 had their primary tumor removed, and the team matched 353 pairs of similar patients to compare fairly.

In the matched groups, patients who had surgery lived far longer. Median overall survival reached twenty-six months against eight, and cancer-specific survival showed the same wide gap. Adjusted models put the risk of death at roughly half for the surgery group. Extra checks supported the pattern, and the link looked stronger in patients who never received chemotherapy and in those with smaller tumors. The authors are careful to call this an association from registry records, since doctors choose surgery for patients they judge fit enough.

Catalog record

Source: https://europepmc.org/article/MED/PMC13437322